Madrigal's blockbuster drug gaining FDA approval this March has opened the doors to a wave of therapeutics from Eli Lilly, Boehringer Ingelheim, AstraZeneca, Amgen, Akero Therapeutics and more that hold huge promise in Phase 1, 2, and 3 clinical trials.  Paired with the boom of GLP-1s, these milestones have reinvigorated investment throughout the metabolic space.

The 8th MASH Drug Development Summit was the perfect forum to unite and discuss the evolving drug development opportunity for MASH and metabolic diseases. From optimizing clinical trial design to overcoming regulatory challenges, combatting fibrosis, navigating GLP-1 usage, optimizing RWE integration and achieving accurate non-invasive biomarkers, you couldn't find this industry-led insight anywhere else.   

We joined 120+ C-Level cardiometabolic stakeholders and thought leaders to make key connections, gained competitive insights and heard the latest data to shape the future of our MASH development pipeline.